BHC analyst estimates
Bausch Health (BHC) analyst ratings, the average price target and its range, and every firm's latest call.
BHC analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 29, 2026 | Jefferies | Bausch Health Companies (BHC) PT Raised to $8 at Jefferies | $8.00 |
| Oct 8, 2026 | RBC Capital | RBC Capital Reiterates Sector Perform Rating on Bausch Health Companies (BHC) | $9.00 |
| Jan 7, 2026 | Truist Financial | Bausch Health price target raised to $8 from $7 at Truist | $8.00 |
| Dec 8, 2025 | Barclays | Bausch Health initiated with an Equal Weight at Barclays | $8.00 |
| Oct 23, 2024 | RBC Capital | Bausch Health price target raised to $10 from $8.50 at RBC Capital | $10.00 |
| Jul 25, 2024 | Truist Financial | Bausch Health price target lowered to $7 from $8 at Truist | $7.00 |
| Jul 10, 2024 | Raymond James | Bausch initiated with Market Perform on Xifaxan risk at Raymond James | $8.00 |
| Apr 29, 2024 | Piper Sandler | Bausch Health Companies (BHC) PT Raised to $9 at Piper Sandler | $9.00 |
| Apr 23, 2024 | RBC Capital | Bausch Health Companies (BHC) PT Lowered to $11 at RBC Capital | $11.00 |
| Apr 11, 2024 | Jefferies | Jefferies on BHC (BHC): 'We see this as an extremely positive outcome for BHC and removes a key barrier to executing the spin' | $16.00 |
| Apr 5, 2024 | RBC Capital | Bausch Health Companies (BHC) PT Raised to $12 at RBC Capital | $12.00 |
| Sep 9, 2022 | Piper Sandler | Piper Sandler Maintains Neutral on Bausch Health Companies, Lowers Price Target to $6 | $6.00 |
| Jul 26, 2022 | RBC Capital | RBC Capital Maintains Outperform on Bausch Health Companies, Lowers Price Target to $12 | $12.00 |
| May 13, 2022 | RBC Capital | RBC Capital Maintains Outperform on Bausch Health Companies, Lowers Price Target to $17 | $17.00 |
- 2 firms rate BHC: 0 buy, 2 hold, 0 sell.
- The average price target is $8.50 from 2 analysts, from $8.00 to $9.00.
Updated 2026-11-02 23:10 UTC